PremiumCompany AnnouncementsSunshine Biopharma Closes $2.46 Million Direct Offering 3 Penny Stocks to Watch Now, 4/3/25 Sunshine Biopharma Reports 78% Revenue Growth and Key Developments in 2022 PremiumThe FlySunshine Biopharma signs agreement for rights to market two generic antibiotics Sunshine Biopharma in strategic deal for new generic antibiotics in Canada Sunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rights PremiumThe FlySunshine Biopharma announces research results on K1.1 mRNA product Sunshine Biopharma launches generic prescription drug Sunshine Biopharma reports Q3 revenue $8.4M vs. $5.96M last year 
